Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes supportive care products. The Company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients. Its lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS. The Company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for childhood catastrophic epilepsy syndromes, and other product candidates, including other dronabinol line extensions and sublingual spray product candidates.